<DOC>
	<DOCNO>NCT02215811</DOCNO>
	<brief_summary>This multi-center , open-label , non-randomized control trial . Patients viral-induced acute respiratory distress syndrome ( ARDS ) extracorporeal membrane oxygenation ( ECMO ) eligible . Ten patient enrol receive allogeneic bone marrow-derived mesenchymal stromal cell ( BM-MSC ) . Ventilator parameter well preoperative clinical characteristic postoperative clinical outcome register . Routine blood sampling , radiography , bronchioalveolar lavage perform pre- postoperatively . Spirometry , quality life assessment , 6 minute walk test perform postoperatively . All available data collect prospectively . Follow-up 12 month . Informed consent obtain relative patient meet inclusion criterion initiation study-specific procedure .</brief_summary>
	<brief_title>Treatment Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>â‰¥ 18 year age Viralinduced acute respiratory distress syndrome Ventilator treatment Extracorporeal membrane oxygenation treatment Relatives provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Extracorporeal membrane oxygenation</keyword>
</DOC>